Updated phase 2 DUBHE-C-204 trial data shows iparomlimab/tuvonralimab with chemotherapy, with or without bevacizumab, yields a 75.9% objective response rate in recurrent/metastatic cervical cancer.
Treosulfan gains FDA approval for allogeneic hematopoietic stem cell transplantation conditioning in AML and MDS, offering a new option for adult and pediatric patients.
Combination therapy with iparomlimab and tuvonralimab alongside chemotherapy demonstrates encouraging responses in patients with recurrent or metastatic cervical cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.